Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD). Mortality data specific to patients with ADPKD is currently lacking; thus, the aim of this study was to estimate mortality in patients with ADPKD.
Methods: We analyzed data from the United States Renal Data System (USRDS) for patients with ADPKD available during the study period of 01/01/2014-12/31/2016, which included a cohort of patients with non-ESRD chronic kidney disease (CKD) and a cohort of patients with ESRD. Mortality rates with 95% confidence intervals (CIs) were calculated overall and by age group, sex, and race for the full dataset and for a subset of patients aged ≥ 65 years. Adjusted mortality hazard ratios (HRs) were calculated using Cox regression modeling by age group, sex, race, and CKD stage (i.e., non-ESRD CKD stages 1-5) or ESRD treatment (i.e., dialysis and transplant).
Results: A total of 1,936 patients with ADPKD and non-ESRD CKD and 37,461 patients with ADPKD and ESRD were included in the analysis. Age-adjusted mortality was 18.4 deaths per 1,000 patient-years in the non-ESRD CKD cohort and 37.4 deaths per 1,000 patient-years in the ESRD cohort. As expected, among the non-ESRD CKD cohort, patients in CKD stages 4 and 5 had a higher risk of death than patients in stage 3 (HR = 1.59 for stage 4 and HR = 2.71 for stage 5). Among the ESRD cohort, patients receiving dialysis were more likely to experience death than patients who received transplant (HR = 2.36). Age-adjusted mortality among patients aged ≥ 65 years in the non-ESRD CKD cohort was highest for Black patients (82.7 deaths per 1,000 patient-years), whereas age-adjusted mortality among patients aged ≥ 65 years in the ESRD cohort was highest for White patients (136.1 deaths per 1,000 patient-years).
Conclusions: Mortality rates specific to patients aged ≥ 65 years suggest racial differences in mortality among these patients in both non-ESRD CKD and ESRD cohorts. These data fill an important knowledge gap in mortality estimates for patients with ADPKD in the United States.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10870477 | PMC |
| http://dx.doi.org/10.1186/s12882-024-03484-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease.
BMC Nephrol
October 2024
Department of Nephrology, China-Japan Friendship Hospital, No. 2 East Yinghuayuan Street, Chaoyang District, Beijing, 100029, China.
Introduction: The role of complement system in late stage of IgA nephropathy (IgAN) remains unknown. We therefore investigated the effects of complement system on worsening kidney function in advanced (stage 4 CKD) IgAN.
Methods: Renal specimens of 69 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2021, were stained using immunofluorescence (IF) and immunohistochemistry (IHC) for glomerular complement components.
Evaluation of complications in patients with mandible fractures undergoing chronic kidney disease in the United States.
BMC Oral Health
September 2024
Department of Pediatric Dentistry, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, 510055, China.
Background: This research aims to assess the demographic characteristics, prevalence, outcomes, and complications in chronic kidney disease (CKD) patients following mandible fractures in the United States using a nationally representative database.
Methods: We analyzed data from the National Inpatient Sample from 2010 to 2019 in the United States. Patients with mandible fractures were categorized into three groups based on the International Classification of Diseases, Ninth and Tenth Revisions (ICD-9-CM and ICD-10-CM): end-stage renal disease (ESRD), non-ESRD CKD, and healthy kidney function.
Complement C3a/C3aR and C5a/C5aR deposits accelerate the progression of advanced IgA nephropathy to end-stage renal disease.
Clin Exp Med
June 2024
Department of Nephrology, China-Japan Friendship Hospital, No. 2 East Yinghuayuan Street, Chaoyang District, Beijing, 100029, China.
Article Synopsis
- IgA nephropathy (IgAN) is a major cause of end-stage kidney disease (ESRD), with complement system activation playing a crucial role in its progression.
- A study on 75 patients revealed that lower eGFR and glomerular C3 deposition are significant predictors of progression to ESRD over a median follow-up of 15 months.
- Moreover, higher levels of complement components C3a, C3aR, C5a, and C5aR were found in ESRD patients, indicating their potential link to faster kidney function decline in advanced CKD stages.
Mortality risk in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol
February 2024
University of Maryland School of Medicine, Baltimore, MD, USA.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD). Mortality data specific to patients with ADPKD is currently lacking; thus, the aim of this study was to estimate mortality in patients with ADPKD.
Methods: We analyzed data from the United States Renal Data System (USRDS) for patients with ADPKD available during the study period of 01/01/2014-12/31/2016, which included a cohort of patients with non-ESRD chronic kidney disease (CKD) and a cohort of patients with ESRD.
Transcatheter left atrial appendage occlusion in patients with chronic kidney disease: a systematic review and meta-analysis.
Clin Res Cardiol
October 2024
Toronto General Hospital Research Institute, University Health Network, 10th Floor Eaton North, Room 237, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Article Synopsis
- Chronic kidney disease (CKD) increases the risk of embolic stroke, complicating anticoagulation therapy; left atrial appendage occlusion (LAAO) is being explored as a safer alternative for these patients.
- A systematic review of 15 studies (77,780 patients) found that CKD patients were older with more comorbidities, and while LAAO presented similar procedural risks to non-CKD patients, they faced higher rates of in-hospital acute kidney injury, bleeding, and mortality.
- Despite the elevated risks, LAAO appears to effectively prevent cardioembolic events in patients with CKD, though the adverse outcomes can be linked to the overall
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!